Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Inherited Metabolic Disease
Published in: Journal of Inherited Metabolic Disease 1/2011

Open Access 01-02-2011 | Letter to the Editors

Letter concerning “Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha”, by Tanaka et al.

Authors: Gabor E. Linthorst, Johannes M. F. G. Aerts

Published in: Journal of Inherited Metabolic Disease | Issue 1/2011

Login to get access

Excerpt

Dear editor, …
Literature
Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG (2004) Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. Kidney International 66(4):1589–1595CrossRefPubMed
Linthorst GE, Vedder AC, Ormel EE, Aerts JM, Hollak CE (2006) Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands. Nephrology, Dialysis, Transplantation 21(2):355–360CrossRefPubMed
Ohashi T, Sakuma M, Kitagawa T, Suzuki K, Ishige N, Eto Y (2007) Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. MolGenetMetab 92(3):271–273
Schellekens H (2008) The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative. Clinical therapeutics 30(Suppl B):S50–S51CrossRefPubMed
Tanaka A, Takeda T, Hoshina T, Fukai K, Yamano T (2010) Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha. J Inherit Metab Dis [Epub ahead of print]
Whitfield PD, Calvin J, Hogg S et al (2005) Monitoring enzyme replacement therapy in Fabry disease–role of urine globotriaosylceramide. J nherit Metab Dis 28(1):21–33
Metadata
Title
Letter concerning “Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha”, by Tanaka et al.
Authors
Gabor E. Linthorst
Johannes M. F. G. Aerts
Publication date
01-02-2011
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 1/2011
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-010-9219-y

Other articles of this Issue 1/2011

Journal of Inherited Metabolic Disease 1/2011 Go to the issue

Homocysteine and B-Vitamin Metabolism

LMBRD1: the gene for the cblF defect of vitamin B12 metabolism

Homocysteine and B-Vitamin Metabolism

Cobalamin C defect: natural history, pathophysiology, and treatment

Homocysteine and B-Vitamin Metabolism

Determination of cystathionine beta-synthase activity in human plasma by LC-MS/MS: potential use in diagnosis of CBS deficiency

Homocysteine and B-Vitamin Metabolism

The homocysteine controversy

Editorial

Foreword to special issue on homocysteine disorders

Original Article

Acute liver failure with subsequent cirrhosis as the primary manifestation of TRMU mutations
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits